Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Vaccine ; 40(2): 178-182, 2022 01 21.
Artigo em Inglês | MEDLINE | ID: mdl-34863619

RESUMO

France is one of the most vaccine-hesitant countries in the world, including for coronavirus disease 2019 (COVID-19). After 10 months of restrictive measures and media coverage of the dangers of COVID-19, French attitudes towards a vaccine continue to deteriorate. The communication strategies of the government have not helped; in fact, they have made the situation worse. Empirical studies on the national strategy for management of the COVID-19 pandemic in France have shed light on the reasons for vaccine hesitancy. These studies have identified four pillars for the vaccination strategy: i) Communication regarding the importance of herd immunity, ii) making healthcare workers the focus of the vaccination campaign, iii) citizen mobilization and guaranteed consultations, and iv) access to free vaccines without delay. This paper discusses the evidence supporting this strategy.


Assuntos
COVID-19 , Vacinas , Vacinas contra COVID-19 , França , Humanos , Programas de Imunização , Pandemias , SARS-CoV-2 , Vacinação , Hesitação Vacinal
2.
Vaccine ; 36(10): 1285-1296, 2018 02 28.
Artigo em Inglês | MEDLINE | ID: mdl-29397227

RESUMO

BACKGROUND: CMV infections are the most frequent congenital infections worldwide. AIM: Assess the cost-effectiveness of vaccination strategies of adolescent girls vs. current practice (hygiene counseling) to prevent CMV seroconversions during pregnancy in France. METHOD: A Markov decision-tree model simulated overtime the trajectory of a single fictive cohort of 390,000 adolescent women aged 14 years old, living in France. Impact of vaccination was explored until the end of their reproductive live 40 years later. STRATEGIES COMPARED: "S1: No vaccination" (current practice); "S2: Routine vaccination"; "S3: Screening and vaccination of the seronegative". MODEL PARAMETERS: Seroconversion rate without vaccination (0.035%/pregnant woman-week); fetal transmission risk (41%). Vaccine vs. no vaccination: a 50% decrease in maternal seroconversions. OUTCOMES: Quality-Adjusted Life-Years (QALYs) of the cohort-born babies; discounted costs; Incremental Cost-Effectiveness Ratio (ICER). RESULTS: S2 was the most effective strategy (with 35,000 QALYs gained) and the most expensive (€211,533,000); S1 was the least effective and least costly (€75,423,000). ICERs of strategy S3 vs. S1, and S2 vs. S3 were 6,000€/QALY gained (95% uncertainty range [2700-13,300]) and 16,000€/QALY [negative ICER (S3 dominated by S2) - 94,000] gained, respectively; highly cost-effective because ICER < 1∗France's GPD/capita = €30,000. SENSITIVITY ANALYSIS: If the seroprevalence was >62% (vs. 20% in the base case), S3 would become the most efficient strategy. CONCLUSION: In France, systematic vaccination of adolescent girls was the most efficient strategy to prevent maternal seroconversions. If the population was less than 62% immune, systematic screening and vaccination of susceptibles would become the most cost-effective approach.


Assuntos
Análise Custo-Benefício , Citomegalovirus/imunologia , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/imunologia , Vacinação , Adolescente , Feminino , França/epidemiologia , Custos de Cuidados de Saúde , Humanos , Incidência , Transmissão Vertical de Doenças Infecciosas , Cadeias de Markov , Avaliação de Resultados em Cuidados de Saúde , Infecções por Papillomavirus/transmissão , Vacinas contra Papillomavirus/administração & dosagem , Vacinas contra Papillomavirus/economia , Gravidez , Vigilância em Saúde Pública , Fatores Sexuais , Vacinação/economia , Vacinação/métodos
3.
Rev Epidemiol Sante Publique ; 55(5): 365-73, 2007 Oct.
Artigo em Francês | MEDLINE | ID: mdl-17851008

RESUMO

BACKGROUND: A subject's vital status is essential for epidemiological studies. This information may be obtained for large numbers of patients with different methods, but these are often expensive. This study was aimed at assessing the performance of patient vital status determination using a record linkage method between hospital data and national mortality data once the information was made anonymous in compliance with French legislation. METHODS: All patients hospitalised in the Gustave-Roussy Institute, a cancer center in Villejuif France, were eligible for inclusion if they lived in France (mainland or Overseas Departments). The study cohort included patients admitted for the first time for malignant or suspected malignant-tumor during the period 1998-2000. Nominal data from the Gustave Roussy Institute hospital files as well as from the French National Institute of Statistics and Economic Studies (INSEE) mortality databases were then anonymised using irreversible hash coding. Once anonymised, the Gustave Roussy Institute and INSEE mortality databases were linked using the Jaro probabilistic method. Record linkage involved the following variables: birth name, first given name and birth date, along with the INSEE code of birth place. RESULTS: 10,089 patients were included. The linkage record results were very satisfactory for all the patients included; the percentage of those properly classified was 97.2%, sensitivity was 94.8% and specificity 99.5%. The performance of the probabilistic record linkage method on anonymised data was very satisfactory (sensitivity 96.8% and specificity 99.8%) for determining vital status for patients born in France, suffering from cancer and in-patients at the Institute Gustave-Roussy. Results were inferior for patients born abroad (sensitivity 82.8% and specificity 97.7%) but the method achievements may be enhanced by additional manual validation steps. CONCLUSION: Probabilistic linkage on data rendered anonymous enables to obtain information on vital status for a great number of subjects at low cost, in compliance with French legislation.


Assuntos
Registros Hospitalares , Registro Médico Coordenado , Mortalidade , Sistema de Registros , Estatísticas Vitais , Anônimos e Pseudônimos , Institutos de Câncer/estatística & dados numéricos , Estudos de Coortes , Bases de Dados Factuais , França/epidemiologia , Humanos , Neoplasias/epidemiologia , Neoplasias/mortalidade , Sensibilidade e Especificidade
4.
Med Mal Infect ; 46(2): 67-71, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26905394

RESUMO

The cost of HIV care in European countries is high. Direct medical costs, in France, have been estimated at 500,000 Euros per patient's lifetime (20,000 Euros/year/patient). Overall, 73% of these costs are related to antiretroviral treatments. In the current financial crisis context, some European countries are beginning to make economic decisions on the drugs to be used. These approaches are likely to become more frequent. It is obviously essential to prescribe the most effective, appropriate, best tolerated, and easy-to-use antiretroviral treatments to patients. However, while taking the above into consideration, and if various treatment options or combinations are available, cost should also be considered in the treatment choice. One may thus reflect on the use of generic antiretroviral agents as they have just been launched in France. We aimed to review the cost and cost-effectiveness of generic antiretroviral drugs and to review treatment strategies other than generic drugs that could help reduce HIV-related costs. HIV clinicians should consider treatment costs to avoid any future coercive measures.


Assuntos
Antirretrovirais/economia , Antirretrovirais/uso terapêutico , Análise Custo-Benefício , Medicamentos Genéricos/economia , Medicamentos Genéricos/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Europa (Continente) , Humanos
5.
Transplantation ; 77(6): 854-8, 2004 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-15077026

RESUMO

BACKGROUND: The authors have previously shown that mononuclear cells derived from patients with resistant chronic graft-versus-host-disease (GVHD) express high calcineurin (CN) activity, suggesting that in vitro assessment of CN activity may be a useful index to estimate the degree of immunosuppression afforded by cyclosporine A (CsA). The goal of this study was to assess CN activity during the first 2 months after allogeneic stem-cell transplantation (SCT) and to correlate its evolution with the occurrence of acute GVHD. METHODS: Thirty-one allogeneic SCT recipients were enrolled during a 21-month period. All received GVHD prophylaxis with CsA (2 mg/kg/day) and methotrexate (on days 1, 3, and 6). CN activity was measured before transplant, and then once weekly, for at least 2 months. RESULTS: Eighteen patients developed acute grade II or higher GVHD at a median time of 22.5 days and were treated with steroids. CN activity was significantly increased in these 18 patients when compared with 13 patients who did not develop GVHD. Analysis involving the receiver operating characteristic curve demonstrated that acute grade II or higher GVHD can be predicted with a sensitivity of 89% and a specificity of 54% with the use of a cutoff value of 28 pmol RII/mg proteins/min of CN activity. CONCLUSIONS: CN activity appears to be a promising therapeutic test to predict acute GVHD after allogeneic SCT. This functional assessment of the in vivo efficacy of CsA opens new insights for CsA dose adjustment-in particular, the administration of its most efficient dose instead of its maximal tolerated dose, as is currently performed.


Assuntos
Biomarcadores/sangue , Calcineurina/sangue , Doença Enxerto-Hospedeiro/diagnóstico , Terapia de Imunossupressão , Leucemia/cirurgia , Transplante de Células-Tronco , Adulto , Transplante de Medula Óssea/imunologia , Feminino , Doença Enxerto-Hospedeiro/sangue , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Imunossupressores/uso terapêutico , Leucemia/sangue , Masculino , Pessoa de Meia-Idade , Doadores de Tecidos , Transplante Homólogo
6.
Rev Neurol (Paris) ; 160(2): 256-60, 2004 Feb.
Artigo em Francês | MEDLINE | ID: mdl-15034486

RESUMO

Many studies have shown that high blood pressure and, to a lesser extent, other vascular risk factors could be the target of interventions aiming to reduce the incidence of dementia. Two large controlled trials have demonstrated that blood pressure lowering drugs have a significant effect on the risk of dementia including Alzheimer's disease. On another hand, large epidemiological studies have shown associations between different vascular factors and dementia. Overall, these data suggest that interventions aiming to reduce the level of vascular risk factors might prevent dementia. The expected benefit of these interventions could be estimated from data provided by epidemiological studies, but large population-based controlled studies are needed to demonstrate the efficacy of preventive interventions.


Assuntos
Demência/prevenção & controle , Fatores Etários , Anti-Hipertensivos/uso terapêutico , Estudos de Coortes , Fatores de Confusão Epidemiológicos , Demência/epidemiologia , Demência/etiologia , Demência Vascular/epidemiologia , Demência Vascular/etiologia , Demência Vascular/prevenção & controle , Humanos , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Incidência , Fatores de Risco
9.
Br J Haematol ; 115(3): 630-41, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11736948

RESUMO

To evaluate the long-term immune reconstitution after allogeneic haematopoietic stem cell transplantation (SCT), we prospectively screened standard immune parameters in a series of 105 patients, at a median time of 15 months after SCT. Analysing lymphoid phenotypes, in vitro immune functions and immunoglobulin levels, we found that, more than 1 year post SCT, cellular and humoral immunity was still altered in a significant number of patients. CD4+ T cells were < 200/microl in one third of patients, and the CD4/CD8 ratio was still reversed in 78% of patients. Almost all patients showed positive T-cell responses against mitogens, but antigen-specific proliferation assays identified 20% to 80% of non-responders. B-cell counts were reconstituted in 61% of the patients, but levels of total immunoglobulins were still low in 59%. In multivariate analyses, human leucocyte antigen (HLA) disparity between donor and recipient and chronic graft-versus-host disease were the leading causes affecting immune reconstitution. Interestingly, cytomegalovirus (CMV) infections were strongly associated with normal CD8+ T-cell counts. Studying the impact of impaired immune reconstitution on the rate of infections occurring in the 6 years following screening, we identified three parameters (low B-cell count, inverted CD4/CD8 ratio, and negative response to tetanus toxin) as significant risk factors for developing such late infections.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Leucemia/imunologia , Leucemia/terapia , Adolescente , Adulto , Azatioprina/uso terapêutico , Linfócitos B/imunologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Ciclosporina/uso terapêutico , Infecções por Citomegalovirus/imunologia , Quimioterapia Combinada , Feminino , Seguimentos , Glucocorticoides/uso terapêutico , Doença Enxerto-Hospedeiro/imunologia , Humanos , Imunossupressores/uso terapêutico , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estudos Prospectivos , Fatores de Risco , Toxina Tetânica/administração & dosagem , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa